Table 2 Surgical and pathological outcomes.
Overall (n = 516) | Limited-PLND group (n = 283) | Non-PLND group (n = 233) | P-value | |
|---|---|---|---|---|
Surgery type, n (%) | < 0.001 | |||
RARP | 379 (73.4) | 152 (53.7) | 227 (97.4) | |
RRP | 137 (26.6) | 131 (46.3) | 6 (2.6) | |
Median operation time, min (IQR) | 156 (131–184) | 152 (121–182) | 161 (138–189) | 0.001 |
Median blood loss, mL (IQR) | 50 (20–243) | 100 (25–735) | 25 (10–50) | < 0.001 |
Prostatectomy Gleason score, n (%) | < 0.001 | |||
No residual tumor | 55 (10.7) | 29 (10.2) | 26 (11.2) | |
6 (3 + 3; ISUP GG1) | 3 (0.6) | 1 (0.4) | 2 (0.9) | |
7 (3 + 4; ISUP GG2) | 12 (2.3) | 1 (0.4) | 11 (4.7) | |
7 (4 + 3; ISUP GG3) | 63 (12.2) | 11 (3.9) | 52 (22.3) | |
8 (4 + 4, 3 + 5, 5 + 3; ISUP GG4) | 21 (4.1) | 19 (6.7) | 2 (0.9) | |
9, 10 (4 + 5, 5 + 4, 5 + 5; ISUP GG5) | 362 (70.2) | 222 (78.4) | 140 (60.1) | < 0.001 |
Pathological tumor stage, n (%) | 0.584 | |||
ypT0 | 55 (10.7) | 29 (10.2) | 26 (11.2) | |
ypT2 | 314 (60.9) | 168 (59.4) | 146 (62.7) | |
ypT3 | 147 (28.5) | 86 (30.4) | 61 (26.2) | 0.327 |
Surgical margin positive, n (%) | 44 (8.5) | 17 (6.0) | 27 (11.6) | 0.027 |
Median number of dissected nodes, n (IQR) | 4 (3–7) | |||
Number of positive nodes, n (%) | ||||
0 | 281 (99.2) | |||
1 | 1 (0.4) | |||
2 | 1 (0.4) | |||
Biochemical recurrence, n | 85 | 55 | 30 | |
Cancer-specific mortality, n | 5 | 4 | 1 | |
All-cause mortality, n | 13 | 10 | 3 | |
Median follow-up periods, months (IQR) | 57 (31–81) | 77 (63–94) | 34 (20–46) | < 0.001 |
